Epidermal growth factor receptor tyrosine kinase inhibitors

British Journal of Cancer

Volumn 90, Issue 12, 2004, Pages 2250-2255

  Ranson, M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

CI 1033, ZD6474; EKB 569; Epidermal growth factor receptor; Erlotinib; Gefitinib; GW 572016; PKI 166; Tyrosine kinase

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CANERTINIB; CARBOPLATIN; CGP 59326; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; PACLITAXEL; PD 0183805; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VANDETANIB; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADVANCED CANCER; ANOREXIA; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DIARRHEA; DISEASE MARKER; DOSE RESPONSE; DRUG TOLERABILITY; HORMONAL THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; PRIORITY JOURNAL; RADIOTHERAPY; RASH; SHORT SURVEY; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TUMOR REGRESSION; VOMITING; DRUG ANTAGONISM; LUNG TUMOR; PHYSIOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 3042782959     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601873     Document Type: Short Survey

References (52)

1. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients; histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124
2. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, Averbuch S, Baselga J (2003) ZD1839, a specific epidermal growth factor receptor (EFGR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283
3. Arteaga CL (2003b) ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284: 122-130
4. Arteaga CL (2003a) Targeting HER/EGFR; a molecular approach to cancer therapy. Semin Oncol 30(Suppl 7): 3-14
5. Bianco R, Shin I, Ritter Ca, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis Pa, Mills GB, Arteaga CL (2003) Loss of PTEN.MMAC1/TEP in EGF receptor expressing tumour cells counteracts the antitumour action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812-2822
6. Baker CH, Solorzano CC, Fidler IJ (2002) Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signalling for therapy of metastatic human pancreatic cancer. Cancer Res 62: 1996-2003
7. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected solid tumour types. J Clin Oncol 20: 4292-4302
8. Cappuzzo F, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, de Rosa M, Villa E, Crino L (2003) Gefitinib in pre-treated non-small cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21: 2658-2663
9. Chan KC, Knox F, Woodburn JR, Slamon D, Potten CS, Bundred NJ (2000) EGFR tyrosine kinase inhibition decreases epithelial proliferation in DCIS of the breast whereas c-erbB2 blockade does not. Proc Am Assoc Cancer Res 41: 482
10. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G (2003) Antitumour effects of ZD6474, a small molecule vascular endothelial growth factor receptor kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9: 1546-1556
11. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Yokes EE (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987
12. Daneshmand M, Parolin DA, Hirte HW, Major P, Goss G, Stewart D, Batist G, Miller WH, Mathews S, Seymour L, Lorimer IA (2003) A pharmacodynamic study of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 9: 2457-2464
13. Forsythe B, Faulkner K (2003) Safety and tolerability of gefitinib (Iressa, ZD1839) in advanced SCLC: overview of clinical experience. Poster presented at the ERS 13th Annual Cogress, Vienna, Austria, September 27-October 1, Poster P327
14. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard YJ, Nichiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomised phase II trial of gefitinib for previously treated patients with advanced non small cell lung cancer. J Clin Oncol 21: 2237-2246
15. Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Harper ME, Wakeling AE, Nicholson RI (2001) The EGFR-selective tyrosine kinase inhibitor ZD1839 (Iressa) is an effective inhibitor of tamoxifen resistant breast cancer growth. Proc Am Soc Clin Oncol 20: 47
16. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: A phase III trial- INTACT 1. J Clin Oncol 22: 777-784
17. Harari PM, Huang SM (2002) Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin Radiat Oncol 12: 21-26
18. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM (2002) Selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumours: results of a phase I trial. J Clin Oncol 20: 3818-3825
19. Herbst RS (2003) Erlotinib (Tarceva): An update on the clinical trial program. Semin Oncol 30(Suppl 7): 34-46
20. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: A Phase III trial- INTACT 2. J Clin Oncol 22: 785-794
21. Hidalgo M, Erlichman C, Rowinsky EK, Koepp-Norris J, Jensen K, Boni J, Korth-Bradley D, Zacharchuk C (2002) Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumours. Proc Am Soc Clin Oncol 21: 17
22. Hoekstra R, Dumez H, van Oosterom AT, Sizer KC, Ravera C, Vaidyanathan S, Verweij J, Eskens FA (2002) A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor administered orally in a two week on two week off scheme to patients with advanced cancer. Proc Am Soc Clin Oncol 21: 86
23. Ieki R, Saitoh E, Shibuya M (2003) Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 22: 179-181
24. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139
25. Janmaat MI, Kruyt FA, Rodriguez JA, Giaccone G (2003) Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316-2326
26. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW (2003) Epidermal Growth Factor receptor: mechanisms of activation and signalling. Exp cell Res 284: 31-53
27. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albain KS, Brahmer JR, Sandler A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J, Kay A (2002) A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer patients who have failed platinum and docetaxel based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21: 292
28. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y (1998) Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signalling superiority to receptor heterodimers. EMBO J 17: 3385-3397
29. Malik SN, Siu LL, Rowinsky EK, deGraffenried L, Hammond LA, Rizzo J, Bacus S, Brattain MG, Kreisberg JI, Hidalgo M (2003) Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 9: 2478-2486
30. Matsumori Y, Goto H, Nakataki E, Kanematsu T, Yano S, Wedge S, Ryan A, Sone S (2003) ZD6474 an inhibitor of vascular endothelial growth factor receptor tyrosine kinase activity, inhibits growth of human non-small cell lung cancer metastases that are resistant to treatment with ZD1839. Proc Am Assoc Cancer Res 44: 43
31. Moasser MM, Basso A, Averbuch SD, Rosen N (2001) The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188
32. Murren JR, Papadimitrakopoulou VA, Sizer KC, Vaidyanathan S, Ravera C, Abbruzzese JL (2002) A Phase I dose escalating study to evaluate the biologic activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor in patients with advanced cancer. Proc Am Soc Clin Oncol 21: 95
33. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) in Japanese patients with solid malignant tumours. Ann Oncol 14: 922-930
34. Natale RB, Shak S, Aronson N, Averbuch S, Fox W, Luthringer D, Clark K, Baker J, Cronin M, Agus DB (2003) Quantitative gene expression in non-small cell lung cancer from paraffin embedded tissue specimens: predicting response to gefitinib, an EGFR kinase inhibitor. Proc Am Soc Clin Oncol 22: 190
35. Natale RB, Zaretsky SL (2002) ZD1839 (Iressa): what's in it for the patient? Oncologist 7: 25-30
36. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM (2002) Modulation of epidermal growth factor receptor in endocrine resistant estrogen receptor positive breast cancer. Ann NY Acad Sci 963: 104-115
37. Nemunaitis JJ, Eiseman I, Cunningham C, Lenehan P, Olson S, Bycott P, Schlicht M, Zentgraff R, Shin D, Zinner R (2003) A phase I trial of CI-1033, a pan-erbB tyrosine kinase inhibitor given daily for 14 days every 3 weeks in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22: 243
38. Parra HS, Cavina R, Latteri F, Campagnol E, Zucali P, Roncalli M, Grimaldi GC, Ravasi G, Pedicini V, Santoro A (2002) Epidermal growth factor receptor expression in NSCLC is not useful to predict response to ZD1839 therapy: preliminary results of the institution Clinico Humanitas, Rozzano, Milano. AACR-NCI - EORTC Molecular Targets and Cancer Therapeutics, 19-22 November 2002, Abst 183
39. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, Nadler PI, Bonomi P (2001) A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774 following platinum based chemotherapy in patients with advanced EGFR expressing non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20: 310
40. Perez-Soler R, Ling YH, Lia M, Kroog G, Dai Q, Zou Y, Haigentz M, Iwata KK (2003) Molecular mechanisms of resistance to the HER1/EGFR tyrosine kinase inhibitor erlotinib HCl in human cell lines. Proc Am Soc Clin Oncol 22, Abst 752
41. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs, Feyereislova A, Swaisland H, Rowinsky EK (2002) ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor is well tolerated and active in patients with solid malignant tumors in phase I trial. J Clin Oncol 20: 2240-2250
42. Rinehart JJ, Wilding G, Willson J, Krishnamurthi S, Natale R, Dasse KD, Olson S, Marcy P, Lenehan P, Chakrabarti D (2003) A phase I clinical and pharmacokinetic/food effect study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22: 205
43. Rinehart JJ, Wilding G, Willson J, Krishnamurthi S, Natale R, Mani S, Burnett D, Olson S, Bycott P, Owens-Grillo JK, Hes M, Lenehan P (2002) A phase I and pharmacokinetic study of oral CI-1033, a pan erbB tyrosine kinase inhibitor, in patients with advanced solid tumours. Proc Am Soc Clin Oncol 21: 11
44. Ritter CA, Arteaga CL (2003) The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 30: 3-11
45. Rowinsky EK, Garrison M, Lorusso P, Patnaik A, Hammond L, DeBono J, McCreery H, Eiseman I, Lenehan P, Tolcher A (2003) Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor is feasible on a 7 day on/7 day off schedule: a phase I, pharmacokinetic and food effect study. Proc Am Soc Clin Oncol 22: 201
46. She QB, Solit D, Basso A, Rosen N, Moasser MM (2003) Response and resistance to gefitinib (ZD1839) in HER over-expressing tumor cells is mediated through the PI3K/Akt pathway. Proc Am Ass Cancer Res 44: 359
47. Schiller JH (2003) New Directions in the treatment of solid tumors. Semin Oncol 30(Suppl 1): 49-55
48. Slichenmyer WJ, Elliott WL, Fry DW (2001) CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 28(Suppl 5): 80-85
49. Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, Killion JJ, Fidler IJ (2001) Optimisation for the blockade of the epidermal growth factor receptor signalling for therapy of human pancreatic cancer. Clin Cancer Res 7: 2563-2572
50. Spector N, Raefsky E, Hurwitz H, Hensing T, Dowlati A, Dees C, O'Neil B, Smith A, Mangum S, Burris HA (2003) Safety, clinical efficacy and biologic assessments from EGF10004: a randomised phaseIB study of GW572016 for patients with metastatic carcinomas expressing EGFR or erbB2. Proc Am Soc Clin Oncol 22: 193
51. Wakeling AE, Nicholson RI, Gee JM (2001) Prospects for combining hormonal and non hormonal growth factor inhibition. Clin Cancer Res 7(Suppl 12): 4350-4355
52. Zembutsu eH, Ohnishi Y, Daigo Y, Katagiri T, Kikuchi T, Kakiuchi S, Nishime C, Hirata K, Nakamura Y (2003) Gene-expression profiles of human tumour xenografts in nude mice treated with the EGFR tyrosine kinase inhibitor ZD1839. Int Oncol 23: 29-39